Molecular Docking Study For Adenosine Monophosphate-Activated Protein Kinase Agonist From Syzygium Cumini For Treatment Of Diabetes Mellitus-Type 2

Abstract

Diabetes mellitus has been one of the most frequent diseases in both industrialised and developing countries and it is spreading fast over the globe. It is believed that nearly 30 percentage of diabetic patients depends on alternative or  traditional therapy in some manner. The AMP-activated protein kinase (AMPK) is a conserved cellular energy sensor that seems to have evolved early in the evolution of eukaryotes. Metformin, the most frequently used to treat type 2 diabetes, was discovered to activate it in 2001. Even though the metabolic consequences of AMPK activation were similar to the concept that mediates part of metformin's medicinal effects, it currently looks doubtful that AMPK is the drug's primary target, as explained below. The ways by which natural plant compounds obtained from traditional plant Syzygium cumini activate AMPK are explored. From the study, it was noted that 1,2-Benzisothiazol-3-amine tbdms met the AMPK agonist criteria. The 1,2-Benzisothiazol-3-amine tbdms prodrug was already demonstrated to enhance metabolic activities in people with insulin resistance and prediabetes, and it's being debated if this is mediated in partly by AMPK.